Search

Pediatric Hematology Online Forum

A bimonthly online event about complex cases that early-career doctors might encounter. What is the Pediatric Hematology Online Forum?The forum is an initiative of the Educational Subcommittee of the EHA SWG on Pediatric Hematology.

Read more

Evidence and policy to ensure good clinical practice

Interview with Vinay Prasad MD MPH by Heiko Becker MD, on behalf of YoungEHA

Leaders in the field that have the potential to make a difference, that challenge the way we are doing things, who push our perspective out of our…

Read more

Registration & accommodation

Registration is closed

Individual RegistrationHybrid registration fee includes:

Access to the scientific and educational sessions of the meeting
Networking opportunities to speak with the faculty during breaks and the welcome reception
Coffee/tea breaks on November 2-4 and lunches on November 3 and 4
Access to…

Read more

How to apply for an EHA Kick-off Grant

On this page, we explain all of the actions you'll need to take when submitting an EHA Kick-off Grant application.

Read more

Help disseminate IVDR Questionnaire - Share with diagnostic laboratories in your network

The new EU Regulation on in vitro diagnostic medical devices (IVDR) will come into full effect per May 26, 2022 and will have substantial consequences for diagnostic laboratories.

Read more

Belgium shares EU health priorities for Council Presidency

On December 8, Belgium held a conference to unveil its program for the upcoming Council of the EU Presidency (website), to start on January 1, 2024.

Read more

From bedside to Brussels: hematology at the forefront of EU health policy

Access is at the heart of EHA's European Affairs work. More specifically, equitable and affordable access to innovative therapies that are of clear added benefit from a clinical, patient, and public health perspective.

Read more

Revision of the EU’s pharmaceutical legislation

Background on the reformIn April 2023, the European Commission (EC) published two proposals to revise the existing (and outdated) pharmaceutical legislation. This includes legislation on medicines for children and rare diseases.

Read more